6 recruiting, 5 terminated, 3 completed, 2 active not recruiting. 17 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Recruiting 6, Terminated 5, Completed 3, Active not recruiting 2, Withdrawn 1 |
| Phase 2 | 10 | Recruiting 4, Terminated 3, Active not recruiting 2, Completed 1 |
Follow Onureg: new trials by email Literature Review of Onureg trials Research Report on Onureg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML Azacitidine, APG1252 - AML | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 52 | 2026-05-22 | 2026-10-05 |
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia | Phase 1 / Phase 2 | Recruiting | Jacqueline Garcia, MD | 31 | 2026-02-02 | 2026-02-05 |
| Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome Azacitidine Level -1, Azacitidine Level 0, Azacitidine Level 1 - Myelodysplastic Syndromes | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-01-10 | 2026-04-03 |
| Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2024-10-09 | 2024-09-19 | |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia Venetoclax, Azacitidine, Mitoxantrone - Leukemia, Myeloid Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 30 | 2024-07-21 | 2026-01-15 |
| A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies Onureg - Hepatic Insufficiency, Neoplasms | Phase 1 | Terminated | Bristol-Myers Squibb | 2 | 2024-07-12 | 2026-01-12 |
| Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) Azacitidine, Onureg - Acute Myeloid Leukaemia | Phase 1 | Completed | Hikma Pharmaceuticals LLC | 32 | 2024-05-02 | 2025-09-26 |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia Azacitidine, Uproleselan, Venetoclax - Acute Myeloid Leukemia | Phase 1 | Terminated | Brian Jonas | 16 | 2021-07-02 | 2026-02-23 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia Azacitidine, Magrolimab, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 110 | 2020-07-28 | 2026-04-23 |
| Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement Azacitidine, Pinometostat - Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 1 | 2020-03-06 | 2023-10-18 |
| Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Azacitidine, Gilteritinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 97 | 2019-12-17 | 2026-10-06 |
| Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Azacitidine, Venetoclax - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 51 | 2019-10-01 | 2026-02-12 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2019-02-27 | 2026-07-16 |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies Azacitidine, Ivosidenib, Venetoclax - Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 96 | 2018-03-19 | 2026-09-14 |
Leukemia, Myeloid, Acute (10) · Myelodysplastic Syndromes (7) · Leukemia, Myelomonocytic, Chronic (5) · Hematologic Neoplasms (2) · Leukemia (2) · Myeloproliferative Disorders (2) · Hepatic Insufficiency (1) · Hypereosinophilic Syndrome (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myeloid (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Neutrophilic, Chronic (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Myelodysplastic-Myeloproliferative Diseases (1)
M.D. Anderson Cancer Center (8) · National Cancer Institute (NCI) (2) · Brian Jonas (1) · Bristol-Myers Squibb (1) · City of Hope Medical Center (1) · Hikma Pharmaceuticals LLC (1) · Jacqueline Garcia, MD (1) · Medical College of Wisconsin (1) · University of Colorado, Denver (1)
United States (15) · Argentina (1) · Colombia (1) · Germany (1) · Saudi Arabia (1) · Spain (1)
Nicholas Short (2) · Andrew Kent, MD, PhD (1) · Brian A Jonas (1) · Courtney DiNardo, MD (1) · Guillermo Garcia-Manero (1) · Guillermo M Bravo (1) · Guru Subramanian Guru Murthy, MD, MS (1) · Jacqueline Garcia, MD (1) · Kamal Menghrajani (1) · Monzr M Al Malki, MD (1) · Naval G Daver (1) · Naval G Daver, MD (1) · Samuel Ng, M.D. (1) · Tapan Kadia, MD (1)
PMID 34889407, PMID 36063832, PMID 36841758, PMID 37422688, PMID 38277619, PMID 40073835, PMID 40513054, PMID 41779512, PMID 42200455
P30CA033572 (1), P30CA093373 (1), UM1CA186691 (1)